Survey Highlights Differences In Medicaid Coverage For Substance Use Treatment And Opioid Use Disorder Medications
Survey Highlights Differences In Medicaid Coverage For Substance Use Treatment And Opioid Use Disorder Medications
复制标题
DOI：
10.1377/hlthaff.2016.0623
复制
发表时间：
2016-12-01
期刊：
影响因子：
9.7
通讯作者：
Friedmann, Peter D.
中科院分区：
文献类型：
--
作者：
Grogan, Colleen M.;Andrews, Christina;Friedmann, Peter D.
《平价医疗法案》要求州医疗补助计划为其医疗补助扩大人口提供物质使用障碍治疗，但允许各州决定哪些个人服务是可报销的。为了研究各州如何定义物质使用障碍福利计划，我们使用了2013-14年的数据，这些数据是我们作为正在进行的全国性州医疗补助计划调查的一部分收集的。我们的研究结果强调了美国各地物质使用障碍治疗和阿片类药物使用障碍药物覆盖范围的重要州一级差异。许多州没有涵盖有效药物使用障碍治疗所需的所有护理水平，或美国成瘾医学会标准所定义的有效阿片类药物使用障碍治疗所需的药物，这可能导致低收入人群无法获得所需的服务。
The Affordable Care Act requires state Medicaid programs to cover substance use disorder treatment for their Medicaid expansion population but allows states to decide which individual services are reimbursable. To examine how states have defined substance use disorder benefit packages, we used data from 2013-14 that we collected as part of an ongoing nationwide survey of state Medicaid programs. Our findings highlight important state-level differences in coverage for substance use disorder treatment and opioid use disorder medications across the United States. Many states did not cover all levels of care required for effective substance use disorder treatment or medications required for effective opioid use disorder treatment as defined by American Society of Addiction Medicine criteria, which could result in lack of access to needed services for low-income populations.